Background 4
Antimicrobial susceptibility testing. C. difficile frozen stocks were cultured on TBHI (Brain 1 heart infusion, Fisher Scientific, PA, USA) supplemented with 100 mg/L L-cysteine (Fisher 2 Scientific, PA, USA) and 0.1% taurocholate (TCA) plates at 37˚C for 24 hr. Susceptibility of the 3 C. difficile isolates to antibiotics were analyzed using an Etest (bioMerieux, 4 France) as per manufacturer instructions. Briefly an inoculum of 10 5 cfu/ml of each isolate was 5 applied on a prereduced Brucella agar supplemented with Vitamin K1 and hemin (Hardy 6 Diagnostics, Santa Maria, CA) using a sterile cotton swab. Strips (bioMerieux, 7 France) of cefotaxime (cephalosporin), clindamycin (lincosamides), ciprofloxacin 8 (Fluoroquinolones), levofloxacin (Fluoroquinolones), vancomycin and metronidazole were 9 applied to each plate and incubated at 37˚C for 24 hr anaerobically. The test results were 10 interpreted using human CLSI (The Clinical and Laboratory Standards Institute) breakpoints 11
shown in table 5 [59] . 12
Toxin profiling using Multiplex PCR to identify toxin genes. A multiplex PCR assay 13 described in Presson et al. [60] was used for the detection of C. difficile toxin genes A (tcdA), 14 and B (tcdB), as well as binary toxins (cdtA and cdtB), with 16S rRNA genes used as an 15 internal PCR control. Additionally, the following controls were used in each run i) C. difficile 16 R20291 (a toxigenic strain with a toxin gene profile of tcdA positive, tcdB positive, cdtA/B 17 positive), C. difficile F200 a nontoxigenic strain with a toxin gene profile tcdA negative, tcdB 18 negative, cdtA/B negative [61] , and water control. The PCR reaction mixture contained 25 µL of 19 2X Taq polymerase master mix (New England Biolabs, MA, USA; 1X containing 10 mM HCl, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs, 5% Glycerol, 0.08% IGEPAL® CA-630, 21 0.05% Tween® 20, 25 U/ml Taq DNA Polymerase), 5 µL of genomic DNA, and 12 primers 22 used at the concentration described in Table 1 . Genomic DNA was prepared from C. difficile 23 grown overnight on BHI plates. A loop full of cells was harvested from the plates, and 24 subsequently DNA was extracted using a DNeasy UltraClean Microbial Kit (Qiagen Valencia, 25 9 CA) as per the manufacturer's instructions. Thermocycler conditions used were 10 min at 94°C, 1 followed by 35 cycles of 50 sec at 94°C, 40 sec at 54°C and 50 sec at 72°C, and a final 2 extension of 3 min at 72°C. The reaction products were separated on a 1.5% agarose (Fisher 3 Scientific, PA, USA) gel and detected by GelRed (VWR International PA, USA), staining. 4
Images were captured using Molecular Imager GelDoc TM XR+ (Bio-Rad). 5
Strain typing using fluorescent PCR ribotyping. Ribotyping was done using fluorescent 6 PCR ribotyping of the 16S and the 23S rRNA intergenic spacer sequence as described 7 previously [62] . C. difficile colonies for PCR ribotyping were picked from TBHI plates incubated 8 at 37˚C for 24 hr anaerobically. Isolated colonies were sub-cultured into 5 ml BHI broth and 9 additionally incubated overnight at 37˚C anaerobically. A 1:10 dilution of this culture was 10 heated at 95°C for 15 min and stored at 4°C until later use as template. The PCR reaction 11 consisted of a 25 µL volume that included 12 μL of Promega PCR Master Mix (Fisher Scientific, 12 PA, USA), 0.5 μL forward primer (GTGCGGCTGGATCACCTCCT) and 0.5 μL 6-13 carboxyfluorescein (FAM)-labeled reverse primer (56 14 FAM/CCCTGCACCCTTAATAACTTGACC) that were both adjusted to 10 pmol/μL, 10.5 μL of 15 nuclease free water, and 1 μL of DNA template. The PCR cycling conditions were as follows: 16 95°C for 10 min followed by 35 cycles of (denaturation -95°C for 0.5 min, annealing -55°C for 17 0.5 min, and elongation -72°C for 1.5 min), and final elongation of 72°C for 10 min. The 18 fluorescent PCR amplicons obtained were diluted 1:1000 with sterile DNase/RNase free water. 19
The templates were then loaded on to a capillary electrophoresis plate containing a 1:240 ratio 20 of ROX 1000 size standard and Hi-Di Formamide. The resulting chromatograms were analyzed 21 using Applied Biosystems Peak Scanner Software (v. 1.0). The distribution of peaks were then 22 analyzed against a database characterized and validated by Martinson et al., [62] 23 (https://thewalklab.com/tools/) that matches with known ribotypes with the same peaks. 24
Vero cell cytotoxicity assay of C. difficile positive fecal samples. Fecal C. difficile toxin 1 activity of the samples that tested positive for C. difficile was measured using a Vero cell 2 cytotoxicity assay [63, 64] . Briefly Vero cells were grown and maintained in DMEM media 3 (Gibco Laboratories, MD, USA) with 10% fetal bovine serum (Gibco Laboratories, MD, USA) 4 and 1% Penicillin streptomycin solution (Gibco Laboratories, MD, USA) in a cell culture 5 incubator (37°C and 5% CO2). Trypsin-EDTA (0.25%; Gibco Laboratories, MD, USA) was 6 added to the cells with a contact time of 2-3 min. Cells that came off the flask surface were 7 gently washed with 1X DMEM media and harvested by centrifugation 1,000 RPM for 5 min. 8
Cells were plated at 1 × 10 4 cells per well in a 96-well flat bottom microtiter plate (Corning, NY, 9 USA) , and incubated overnight at 37°C / 5% CO2. Fecal samples were defrosted on ice and a 10 1:10 dilution was made using 1X PBS. The samples were then centrifuged at 1,750 RPM for 5 11 min, and the supernatants were collected from each sample and sterilized by passing them 12 through a single 0.22-µm filter. The sterilized samples were then diluted by 10-fold to a 13 maximum of 10 -6 using 1X PBS. Sample dilutions were incubated 1:1 with PBS or antitoxin 14 (TechLabs, TX, USA) for 40 min at room temperature after which it was added to the Vero 15 cells. Control containing purified C. difficile toxins (A and B; List Biological Labs, CA, USA) and 16 antitoxin were included. Plates were viewed under 200X magnification for Vero cell rounding 17 after an overnight incubation at 37°C / 5% CO2. The cytotoxic titer was defined as the 18 reciprocal of the highest dilution that produced rounding in 80% of Vero cells for each sample. 19 16S rRNA-based bacterial community sequencing using Illumina MiSeq platform. Fecal 20 samples (195) were subjected to community 16S rRNA gene sequencing; 6 samples (2 21 canines, 2 felines, and 2 equines were excluded due to not having enough sample available or 22 poor quality of the sequencing run. Microbial DNA was extracted from the fecal samples using 23 the Mag Attract Power Microbiome kit (Mo Bio Laboratories, Inc.). A dual-indexing sequencing 24 strategy was used to amplify the V4 region of the 16S rRNA gene [65] . Each 20-µl PCR mixture 25 contained 2 µl of 10X Accuprime PCR buffer II (Life Technologies, CA, USA), 0.15 µl of 1 Accuprime high-fidelity polymerase (Life Technologies, CA, USA), 5 µl of a 4.0 µM primer set, 1 2 µl DNA, and 11.85 µl sterile nuclease free water. The template DNA concentration was 1 to 10 3 ng/µl for a high bacterial DNA/host DNA ratio. The PCR conditions were as follows: 2 min at 4 95°C, followed by 30 cycles of 95°C for 20 sec, 55°C for 15 sec, and 72°C for 5 min, followed 5 by 72°C for 10 min. Libraries were normalized using a Life Technologies SequalPrep 6 normalization plate kit as per manufacturer's instructions for sequential elution. The 7 concentration of the pooled samples was determined using the Kapa Biosystems library 8 quantification kit for Illumina platforms (Kapa Biosystems, MA, USA). Agilent Bioanalyzer high-9
sensitivity DNA analysis kit (Agilent CA, USA) was used to determine the sizes of the 10 amplicons in the library. The final library consisted of equal molar amounts from each of the 11 plates, normalized to the pooled plate at the lowest concentration. Sequencing was done on 12 the Illumina MiSeq platform, using a MiSeq reagent kit V2 (Ilumina, CA, USA) with 500 cycles 13 according to the manufacturer's instructions, with modifications [65]. Sequencing libraries were 14 prepared according to Illumina's protocol for preparing libraries for sequencing on the MiSeq 15 (Ilumina, CA, USA) for 2 or 4 nM libraries. PhiX and genomes were added in 16S amplicon 16 sequencing to add diversity. Sequencing reagents were prepared according to the Schloss 17 SOP (https://www.mothur.org/wiki/MiSeq_SOP#Getting_started), and custom read 1, read 2 18 and index primers were added to the reagent cartridge. FASTQ files were generated for paired 19 end reads. 20
Community-sequencing bioinformatic analysis. Analysis of the V4 region of the 16S rRNA 21 gene was done in the statistical programming environment R [66] using the package DADA2 22
[67]. Version 1.8 of the DADA2 tutorial workflow (https://benjjneb.github.io/dada2/tutorial.html) 23 was followed to process the MiSeq data. Forward/reverse read pairs were trimmed and filtered, 24 with forward reads truncated at 230 nt and reverse reads at 160 nt, no ambiguous bases were 25 allowed, and each read required to have less than two expected errors based on their quality 1 scores. Error corrected ASVs were independently inferred for the forward and reverse reads of 2 each sample and then read pairs were merged to obtain amplicon sequence variants (ASVs). 3 Chimeric ASVs were identified and removed. For taxonomic assignment ASVs were compared 4 to the Silva v132 database using the implementation of the RDP naive Bayesian classifier 5 available in the DADA2 R package [68, 69] . A BLASTn web search [58] matched ASV4 to the 6 NCBI 16S reference sequence NR 028611.1 for C. hiranonis strain TO-931. ASVs with at least 7 97% identity to this C. hiranonis 16S sequence were then identified using the BLASTn 8 command-line tool [58] . One canine sample and one equine sample received fewer than 30 9 reads after running DADA2 and so were excluded from subsequent analysis of microbiome 10 profiles. The read depth of the remaining samples ranged from 9338 to 60009 reads. 11 C. difficile and C. hiranonis co-culture assay. 12
Competition assays were developed to test the interactions between C. difficile strain R20291 13 and C. hiranonis TO-931T. Overnight cultures of both strains were grown individually in BHI 14 supplemented with 100 mg/L L-cysteine for C. difficile, and additionally supplemented with 2 uM 15 hemin for C. hiranonis. The cultures were grown anaerobically at 37°C. After 14 h of growth, 16 both cultures were subcultured to 1:10 and 1:5 into BHI plus L-cysteine and hemin, and allowed 17 to grow for 3-4 h. Once both the cultures doubled they were back diluted in fresh BHI plus L-18 cysteine and hemin media to obtain a concentration of 1x10 6 CFU/mL for 1x, 1x10 7 CFU/mL for 19 10x, and 1x10 8 CFU/ mL for 100x. Competition controls included monocultures of 1x C. difficile, 20 1x C. hiranonis, 10x C. hiranonis, and 100x C. hiranonis. C. difficile and C. hiranonis were mixed 21 at 1:1, 1:10, and 1:100 ratios respectively. Appropriate dilutions were plated after 24 h of 22 incubation of all treatments anaerobically at 37 °C. Bacterial enumeration was performed and 23 expressed as Log CFU/mL of culture. 24 Statistical analysis. Fisher's exact test for significance, odds ratios, and confidence intervals 1 for the host metadata-C. difficile associations reported in Table 3 were evaluated using Prism 2 version 7.0 for Windows (GraphPad Software, La Jolla, CA, United States). Statistical 3 significance was set at a p-value of <0.05 for all analyses ( * p < 0.05, * * p < 0.01, * * * p < 0.001, 4 * * * * p < 0.0001). All statistical analysis of the microbiota profiles was performed in R; code and 5 data are available on GitHub at https://github.com/rthanis/animal-cdiff. The phyloseq and vegan 6 R packages were used to obtain diversity indices and ordination plots [70, 71] . Associations of 7 animal type and C. difficile with alpha diversity were measured by a two-sided Wilcoxon rank 8 sum test, and associations with Bray-Curtis beta diversity were done by permanova using the 9 adonis2 function from the vegan package. Differential-abundance analysis was performed 10 using the ALDEx2 R package [72] and visualized with the ggplot2 R package [73] . Logistic 11 regression of C. difficile presence in canines against C. hiranonis and other host variables was 12 performed using the brms R package [74, 75] interface to the Bayesian statistical inference 13 software Stan [76] . 14
Results

15
C. difficile prevalence, ribotype, and toxin gene profiles vary by animal species. 16
Forty-two C. difficile strains were isolated from a total of 201 animal fecal samples submitted to 17 the NC State University Veterinary Hospital MMDL. C. difficile was recovered from 30.8% 18 (33/107) of canines, 11.8% (2/17) of felines, 9.7% (7/72) of equines, and no ovines (0/5). To 19 determine the genetic diversity of the C. difficile strains circulating in animals we characterized 20 the toxin gene profiles and PCR ribotypes of the isolates. C. difficile isolates obtained from all 21 animal groups were subjected to multiplex PCR for detection of genes that encode for toxins A 22 (tcdA), B (tcdB), and binary toxins (cdtA and cdtB). In total, 69% (29/42) of the isolates were 23 positive for at least one of the toxin genes tested, and the rest were non-toxigenic. Five 24 different toxin gene profiles resulted that included 2.4% (1/42) tcdA tcdB cdtA cdtB, 52.4% 25 14 (22/42) tcdA tcdB, 9.5% (4/42) tcdA, 4.7% (2/42) tcdB and 30.9% (13/42) non-toxigenic isolates 1 (Table 1 ). The gene profile tcdA tcdB was the most prevalent accounting for 17/33 of canine, 2 1/2 of feline, and 4/7 of equine C. difficile isolates. Isolates from canines had toxin variant 3 genotypes in addition to the non-variant genotypes. Overall, 18 different known ribotypes were 4 observed and three C. difficile isolates had patterns that did not match the established 5 database ( Table 2) . Different ribotypes were shared between different animal groups. The most 6 frequent canine ribotypes were F014-020 (7/33) and F106 (7/33), followed by FP310 (5/33). 7
The two feline C. difficile isolates belonged to two different ribotypes, FP310 and FP501. All 8 seven equine C. difficile isolates were also from different ribotypes. One equine isolate, 9
belonging to the ribotype 078-126 encoded all four-toxin genes. Ribotypes associated with 10 human CDI were also detected in some canines and equines, F014-020, F106, 078-126, and 11
F002. 12
Most animals carrying toxigenic C. difficile had no detectable toxin activity in their feces. 13
Isolation of toxigenic strains of C. difficile from the feces of animals led us to test if there was 14 detectable toxin activity in the fecal samples using a Vero cell cytotoxicity assay. Toxin activity 15 was below the limit of detection in 39 of the 42 fecal samples that were positive for C. difficile 16 carriage. In two samples the toxin activity levels were low and only resulted in 50% rounding in 17 the highest concentration (data not shown). These samples contained C. difficile isolates 18 belonging to ribotype F106 or F014-020 and belonged to canines, which were treated for non-19 gastrointestinal related issues. The other sample had a titer of 2 Log10 reciprocal dilution toxin 20 per 100µL/mL fecal sample, and contained C. difficile belonging to an unidentified ribotype. 21
This sample also belonged to a canine, which was treated for anorexia and anemia. 22 C. difficile prevalence in canines was not significantly associated with key demographic 23
factors. 24 15
The demographic data of canines and equines, which had the most samples, was analyzed 1 further. The key demographic variables including age, gender, gastrointestinal (GI) health 2 status, and antibiotic use in canines and their association with C. difficile prevalence are 3 presented in Table 3 . The overall proportion of canines with reported GI disease at the time of 4 sampling was 46.3% (48/103). Animals on antibiotics during the time of treatment for which 5 medication data was available was 56.7% (59/104). The study included males (58.6%; 61/104) 6 and females (41.3%; 43/104). A total of 44 different dog breeds with an age range of 3 months 7 to 13 years (median 8 years) were grouped into 4 age categories: <1 yr (6.4%; 5/77), 1-4 yr 8 (18.1%; 14/77), 5-9 yr (38.9%; 30/77), ≥ 10 yr (36.3%; 28/77). A two-sided Fisher's exact test 9 between C. difficile presence and gender, GI health status, or concurrent use of antibiotics in 10 canines all yielded p-values above 0.05 (Table 3) . Antibiotic intake appeared moderately 11 positively associated, with an odds ratio of 1.84 (95% confidence interval (0.80, -4.26); p = 0.2). 12
In an exploratory analysis that considered age as a continuous variable, we did observe a 13 higher prevalence of C. difficile in dogs between 5 and 11 years and lower in younger and older 14 dogs ( Supplementary Figure 1) . 15
C. difficile prevalence in equines is associated with GI health status. 16
The demographic variables and their association with C. difficile prevalence in equines are 17 presented in Table 4 . In equines, 53.8% (35/65) had symptoms indicative of a GI disorder and 18 62.1% (36/58) of the reported cases were known to be on antibiotics. The sampled population 19 included males (60.9%; 39/64) and females (39%; 25/64). Equines were grouped into three age 20 categories <2 (9.6%; 5/52), 2-10 (38.5%; 20/52), >10 (51.9; 27/52) and included 25 different 21
breeds. Age was not tested for significance because of the low number of C. difficile positives 22 under each category. GI health status was positively associated with C. difficile presence 23 (p=0.01 by two-sided Fisher's exact test; odds ratio 95% confidence interval of (1.66, ∞). All 24 16 equine samples from which C. difficile was recovered belonged to animals that had colic or 1 other GI related issues. 2 C. difficile isolates from companion animals were resistant to antibiotics commonly 3 used in clinical settings, but not front line antibiotics used to treat CDI. 4
To further characterize the C. difficile strains isolated from animals, we tested the frequency of 5 resistance to antibiotics used to treat CDI (vancomycin and metronidazole), and those 6 considered as risk factors (cefotaxime, clindamycin, ciprofloxacin, and levofloxacin) for human 7 CDI. All isolates were resistant to cefotaxime and the majority (97%) of them were resistant to 8 ciprofloxacin, whereas resistance to clindamycin and levofloxacin varied (23% and 59% 9 respectively) ( Table 5 ). Only one toxigenic isolate (2.5%, ribotype F014-020) from canine was 10 resistant to metronidazole with a MIC of 512 µg/ml. In all other isolates the MIC for 11 metronidazole remained low (0.38 to 1.5 µg/ml). All C. difficile isolates characterized were 12 susceptible to vancomycin. 13 gene and so it is possible that the C. difficile strain found in these two equine samples contains 23 all three ASVs at different 16S copies. An additional Clostridioides ASV (ASV843) with 24 unknown species identification had 2 nucleotide mismatches from ASV82 and was detected in 1 3/5 ovine samples and no other animals. 2
C. difficile can be detected from animal feces using
We compared the detection of C. difficile via community 16S sequencing to that from the 3 spore-enrichment lab assay. 16S sequencing had good positive predictive value for the results 4 of the lab assay, especially in canines where 19/21 of the samples in which C. difficile was 5 detected by 16S sequencing were also positive for C. difficile presence in the lab assay. The 6 lab assay detected more C. difficile positive samples overall (39 vs. 31) and particularly in 7 canines (31 vs. 21), but each assay detected C. difficile in some samples the other assay did 8 not (Table 6 ). For all subsequent analyses of the effect of C. difficile presence on the 9 microbiota, we therefore define samples as C. difficile positive if C. difficile was detected by the 10 laboratory testing or if ASV82 was detected in the 16S rRNA data. 11
Differences in the fecal microbiota were associated with animal type and C. difficile 12 prevalence. 13
We measured alpha diversity of fecal microbiota samples using inverse Simpson index and 14 evaluated differences between animal type and differences between C. difficile positive and 15 negative cohorts within animal types. The distributions of the inverse Simpson index at three 16 microbial taxonomic ranks (Family, Genus, and ASV) are presented in Figure 2A . At each 17 taxonomic rank, canine and feline samples had similar diversities to each other, as did equine 18 and ovine samples, with canine and feline samples having lower diversities than equine and 19 ovine samples. We considered whether C. difficile presence was associated with alpha 20 diversity within a host animal type, for the two animals (canines and equines) with larger 21 sample sizes ( Supplementary Figure 2) . C. difficile presence was not associated with genus-22 level inverse-Simpson diversity in canines (p = 0.84, two-sided Wilcoxon rank sum test; non-23 parametric 95% confidence interval for the median effect of C. difficile presence (-1.1, 1.2) but 24 was associated with lower genus-level inverse Simpson diversity in equines (p = 0.019, two-25 sided Wilcoxon rank sum test; non-parametric 95% confidence interval for the median effect of 1 C. difficile presence (-7.0, -0.75), with similar patterns observed for family-and ASV-level 2 diversity (Supplemental Figure 2) . 3
To elucidate factors related to the differences and similarities between fecal microbial 4 community structures (β diversity) we performed non-metric multidimensional scaling (NMDS) 5 based on Bray-Curtis dissimilarities between samples at the ASV level. The samples clustered 6 based on animal group ( Figure 2B ). The first axis separates the canines and felines from the 7 equines and ovines, and the second axis separates the ovines from the equines. No effect of 8 C. difficile presence was visually apparent in this cross-species NMDS plot. The presence of C. 9 difficile resulted in a statistically significant but weak shift in the fecal microbial community 10 structure in both canines (permonova, p = 0.0021, R 2 = 0.026) and equines (permonova, p = 11 0.00028, R 2 = 0.030). This result indicates that the degree to which the structure of the whole 12 fecal microbial community could be explained by C. difficile presence or absence was low. 13 C. hiranonis is negatively correlated with C. difficile presence in canines. 14 Next, we sought to determine whether the presence of C. difficile was associated with specific 15 changes in canine fecal microbial communities. We focused on canines due to the high sample 16
number and the high C. difficile prevalence. We performed a compositional principle-17 components analysis (PCA) [71] to visualize the variation in community composition among 18 canine samples and the ASVs driving this variation. The resulting sample ordination shows a 19 weak but apparent association of C. difficile presence with overall community structure (Figure  20 3A). To determine which ASVs drive this association, we performed a differential-abundance 21 analysis against C. difficile presence with the ALDEx2 R package [79] . For each ASV, ALDEx2 22
reports an effect size estimating the difference in the taxon's centered-log-ratio (a measure of 23 relative abundance) between groups (C. difficile positive vs. negative samples) divided by the 24 difference within groups. Figure 3B shows the ASVs with the largest ALDEx2 effect sizes on the 25 19 taxa PCA ordination that match the sample ordination of Figure 3A . Visualizing the relative 1 abundances of the top positive and negatively associated ASVs indicates that many of the top 2 associations are largely driven by differential prevalence (presence/absence) ( Figure 3C ). 3
The largest negative effect size reported by ALDEx2 is that of ASV4. Although this ASV 4
was not assigned to a species from the Silva database, we used BLAST to determine that it 5 exactly matches the 16S V4 region of [Clostridium] hiranonis strain TO-931. We therefore 6 sought to further understand the relationship between [Clostridium] hiranonis with C. difficile in 7 our samples. There are 23 ASVs with >99% similarity to C. hiranonis strain TO-931; these are 8 ASV4 and 22 additional ASVs that differ from ASV4 by 1 bp. These 22 ASVs have lower 9 prevalence than ASV4 and always appear alongside but have lower abundance than ASV4, 10 suggesting a variety of strains of C. hiranonis that carry ASV4 and these other variants at 11 additional copies of the 16S gene. Considering these other ASVs allowed us to identify a 12 possible strain of C. hiranonis that may be particularly negatively associated with C. difficile. 13 ASV62 appears in 19/52 (27%) of C. difficile negative samples but 0/33 of C. difficile positive 14 samples ( Figure 3C ). Bayesian logistic regression of C. difficile presence against the presence 15 of ASV4 with or without ASV62 along with sample variables demonstrates that the negative 16 association of C. difficile with C. hiranonis remains after controlling for antibiotics usage, GI 17 health status, gender, and age and that C. hiranonis carrying ASV62 potentially has a much 18 stronger negative effect on C. difficile presence than other C. hiranonis strains (ASV4 alone: 19 odds-ratio has a 90% credible interval of 0.17-0.57; ASV4 with ASV62: odds-ratio has 90% 20 credible interval of 0.005-0.12). C. hiranonis in felines was also negatively associated with C. To test the hypothesis that there is an exclusionary relationship between C. difficile and C. 3 hiranonis in the canine gut, we developed a co-culture in vitro assay in rich medium. C. difficile 4 and C. hiranonis were grown alone (monoculture) and in concert at different concentrations over 5 a 24 hour period in BHI medium (Figure 4) . C. difficile growth over a 24 hour period was not 6 inhibited by C. hiranonis cells at the 1:1 concentration and even when C. hiranonis outnumbered 7 C. difficile by a factor of 10 (C. difficile to C. hiranonis ratio), whereas C. hiranonis growth was 8 significantly inhibited by 24 hours (Figure 4A and B) . It was only when C. hiranonis outnumbered 9 C. difficile cells by a factor of 100 that C. hiranonis growth was not affected at 24 hours ( Figure  10   4C ). This provides further evidence that there is a relationship between these two strains, but 11 the mechanism of their interaction still requires further study. 12
Discussion 13
The prevalence of C. difficile in the dogs, cats, and horses we studied was substantial, and 14 supports the possibility that millions of Americans may be exposed to C. difficile each year 15 through contact with companion animals. C. difficile was detected in 31% of the canines in our 16 study, which is within the previously reported range (2-40%), although slightly higher than the 17 range (10.5-18.4%) reported from other parts of the U.S, perhaps because our study population 18 was recruited from a tertiary animal hospital [16, 17, 23, 80] . Felines were colonized at 11.8% 19
(2/17) in our study, which is within the previously reported range (2-30%) [16, 22, 24, 26, 48, 20 81] , as was the 9.7% C. difficile carriage rate of equines in our study given the varying age and 21 GI health status of the studied population [16, 31, 32] . Significant variation exists in C. difficile 22 prevalence rates in companion animals reported by different studies, likely due to various 23 factors such as differences in the type of isolation technique, geographic location, and study 24 21 population. Nevertheless, the mounting body of evidence is consistent with a large interface 1 between humans and companion animals carrying C. difficile. 2
The C. difficile strains isolated from companion animal feces in this study, included 3 ribotypes associated with CDI epidemics in humans. Eighteen different C. difficile ribotypes 4 were identified in this study. The most common ribotypes recovered were F014-020 and F106 5 from both canines and equines. Interestingly, a recent epidemiological survey of human C. 6 difficile isolates conducted in the U.S. between 2011 and 2017 reported ribotype 106 as the new 7 dominant ribotype, and the most common isolated from CA-CDI. Ribotype 014-020 was the 8 second most common ribotype among HA-CDI [82] . We also isolated from an equine the 078-9 126 ribotype that is a known epidemic strain in humans often linked to CA-CDI [82]. The 10 nationwide gradual change in circulating ribotypes in humans and the interspecies sharing of the 11 predominant ribotypes warrant increased utilization of a one health framework that can account 12 for potential zoonotic transmission to understand the changing epidemiology of C. difficile. 13
The clinical relevance of C. difficile carriage in dogs and cats remains unclear, but 14 asymptomatic carriage does not preclude transmission to susceptible hosts. In this study, most 15 animals carrying toxigenic C. difficile had no detectable toxin activity in their feces via a Vero cell 16 cytotoxicity assay. This could possibly be explained by toxin break down since the fecal samples 17
were not frozen immediately after collection, but is also consistent with largely asymptomatic 18 carriage in dogs and cats. For example, the three dogs that had detectable toxin activity in the 19 feces did not present any atypical fecal consistency or GI-related issues. Asymptomatic toxin 20 carriage has been previously recognized in canines by Weese et al. [46] , but this does not 21 preclude the possibility of symptomatic CDI developing later or after transmission to a different 22 host species. Asymptomatic carriage where C. difficile is able to colonize, proliferate, and 23 produce toxin is also reported in humans, and its role in disease transmission and the 24 mechanism of protection is currently under active investigation [83] . 25
22
Antimicrobial resistance plays a major role in driving the emergence of epidemic isolates 1 and the associated changes in the epidemiology of C. difficile [84] . The low prevalence in our 2 study of resistance to vancomycin and metronidazole, the front-line antibiotics used to treat CDI 3 in humans, is similar to previous reports in humans and animals [32, 82, 85] , although there are 4 reports of emerging resistance to metronidazole from other parts of the world [86] . Historically 5 clindamycin, later cephalosporins, and more recently fluoroquinolones are recognized as risk 6 agents for CDI in humans. Resistance to clindamycin was found in 23% of the C. difficile 7 isolates in our study. All isolates in our study were resistant to ciprofloxacin a second-generation 8 fluoroquinolone, consistent with patterns in human isolates [87] . Resistance to cefotaxime, a 9 third-generation cephalosporin, was common among all isolates, similar to human studies that 10 report 100% resistance [87, 88] . However, most isolates were sensitive to levofloxacin, a newer 11 third-generation fluoroquinolone. The acquisition of fluoroquinolone resistance by certain 12 epidemic strains (027/BI/NAP1) was the key event linked to their rapid emergence and 13 dissemination in North America [89] . 14 Alterations in the fecal microbiota associated with C. difficile carriage in dogs and horses 15 were limited. In canines the alpha diversity was similar between C. difficile positive and negative 16 cohorts. However, in equines C. difficile prevalence was associated with lower genus-level 17 inverse Simpson diversity very similar to that reported in humans during CDI [51, 90] and 18 asymptomatic carriage [90] . Permanova analysis revealed weak, but significant, differences in 19 community structures between C. difficile positive and negative cohorts in canines and equines. 20
Alterations in the fecal microbiota, specifically a decrease in the abundance of specific species 21 and overall diversity, is associated with CDI in humans [51], yet how the gut microbiota of 22 domestic animals changes in the presence of C. difficile remains unclear. 23
The largest negative association between any detected taxa and C. difficile was with C. 24 hiranonis in dogs and cats. This corroborates the recent report of a similar negative association 25 23 between C. difficile and C. hiranonis in opportunistically collected canine fecal samples [91] . C. 1 hiranonis is a commensal bacterium that encodes the bile acid inducible (bai) operon and is 2 capable of 7α-dehydroxylation of primary bile acids into secondary bile acids. Microbial 3 mediated secondary bile acids are known to play a key role in inhibiting the C. difficile life cycle 4 in vitro [92, 93] . Secondary bile acid synthesis is regulated by 7α-dehydroxylating gut bacteria 5 from the Clostridium cluster XIVa [94] , which includes C. hiranonis and C. scindens. C. scindens 6 was associated with partial colonization resistance against C. difficile in a mouse model [50] , 7 however very little is known about the 7α-dehydroxylating capacity of C. hiranonis in the canine 8 gut [95] and needs to be further investigated [96] . 9
The presence of C. difficile in the co-culture significantly inhibited C. hiranonis growth in a 10 concentration dependent manner in vitro using a co-culture system in rich medium. The 11 mechanisms for this suppression are unknown currently, but we hypothesize that competition of 12 nutrients might play a role via the Stickland reaction [95] or C. difficile could be making an 13 inhibitory product that inhibits other commensals. Recently, Kang et al. found that closely related 14 C. scindens produces a tryptophan-derived antibiotic that is able to inhibit C. difficile [97] . C. 15 difficile was also able to secrete cyclic dipeptides that inhibited C. scindens. More work needs to 16 be done using C. hiranonis strains isolated from canines, as we were unsuccessful with this 17 isolation, in a medium that mimics the canine gut environment. Nevertheless, the commensal 18
Clostridium strains could be a promising probiotic to prevent C. difficile in canines and humans. 19
Conclusions 20
In this study we investigated a potentially important source of C. difficile transmission: the 21 companion animal population. C. difficile carriage was common in dogs, cats, and horses. C. 22
difficile isolates from companion animals included many of the same ribotypes known to cause 23 HA-and CA-CDI in humans, and had similar antimicrobial resistance profiles as those isolated 24 from human populations. The large amount of contact between people and companion animals 25 24 carrying C. difficile, as well as the similarities between C. difficile isolates from humans and 1 companion animals, are consistent with the possibility of zoonotic transmission. However, it will 2 be critical going forward to develop new studies that can rigorously establish that zoonotic 3 transmission of C. difficile is a reality and not just a possibility. Understanding how C. difficile is 4 able to colonize different companion animals and what factors are able to prevent colonization 5 will be important for developing novel therapeutics to eradicate C. difficile in the animal 6 population, and hopefully thereby decreasing CA-CDI cases in humans. O'Neill G, Adams J, Bowman R, Community differences were analyzed by principal components analysis (PCA) and differential-abundance analysis (with ALDEx2) of the CLR-transformed abundances. A) and B) show the first two principal components (PCs), which explain 15% and 7% of the variance. Panel A shows the samples and Panel B shows the top ten positive and negatively associated taxa detected by ALDEx2. C) shows the CLR relative abundance for a subset of differentially abundant ASVs in C. difficile positive and negative samples. These ASVs are the 4 with the largest positive effect size (ASV82, ASV233, ASV331, and ASV37), the 4 with the largest negative effect size (ASV4, ASV10, ASV20, and ASV112), and the lower-prevalence C. hiranonis ASV (ASV62). Violin plots show the estimated distribution of the CLR values in C. difficile positive and negative samples, accounting for uncertainty in each sample due to multinomial sampling error during sequencing. Points indicate the mean CLR value for each sample. The numbers to the right of the violin plots indicate the prevalence of the ASV. Co-culture assays in Brain heart infusion media supplemented with 100 mg/L L-cysteine between C. difficile and C. hiranonis, where cultures were mixed in the ratio of 1:1 (A), 1:10 (B), or 1:100 (C). Colonies were enumerated and expressed as CFU/mL of culture at time points 0 and 24 h for the competition controls (monocultures of C. difficile and C. hiranonis) and the co-cultures (1:1, 1:10, and 1:100). Data presented represents mean ± SD of at least four experiments in A and B and triplicate experiments in C. Statistical significance between 24 h monoculture and the respective co-culture treatments was determined by Student's parametric t-test with Welch's correction (**, p < 0.01; ***, p < 0.001).
